SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-24-001830
Filing Date
2024-01-09
Accepted
2024-01-09 16:05:36
Documents
9
Period of Report
2024-01-09

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm DEF 14A 818393
2 formdef14-a_001.jpg GRAPHIC 5525
3 formdef14-a_002.jpg GRAPHIC 48539
4 formdef14-a_003.jpg GRAPHIC 73558
5 formdef14-a_004.jpg GRAPHIC 105009
6 formdef14-a_005.jpg GRAPHIC 104546
7 formdef14-a_006.jpg GRAPHIC 190889
8 proxy_001.jpg GRAPHIC 308778
9 proxy_002.jpg GRAPHIC 221141
  Complete submission text file 0001493152-24-001830.txt   2277593
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: DEF 14A | Act: 34 | File No.: 001-40101 | Film No.: 24523291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)